Carotid stenting continues to proliferate as a therapy for carotid occlusive disease, despite articles from professional societies urging restraint, [1] [2] [3] [4] the absence of any devices approved by the Food and Drug Administration (FDA), and the nonreimbursement policy of the Health Care Financing Administration. Considering these rather daunting scientific, political, financial, and regulatory disincentives, what has motivated the continued growth of carotid stenting?
First of all, physicians and their patients have been impressed by the apparent simplicity of this less-invasive, percutaneous alternative to carotid surgery. In addition, observational evidence [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and one randomized trial 22 have provided physicians with a sense that the procedure is both safe and effective. However, the history of modern medicine abounds with examples of seemingly efficacious therapies that are shown to lack benefit or even cause harm when subjected to rigorous clinical investigation.
Over the last half decade, a large number of endovascular specialists have gained considerable experience with carotid stenting. This expertise, along with the introduction of dedicated carotid stents and neuroprotection devices, has set the stage for the vascular, interventional, and neurological communities to commit to a rigorous evaluation of this promising therapy.
CAROTID REVASCULARIZATION ENDARTERECTOMY VERSUS STENT TRIAL (CREST)
This multicenter randomized trial, sponsored by the National Institute of Neurological Disorders and Stroke, National Institutes of Health, will compare the efficacy of carotid stenting against carotid endarterectomy (CEA) in symptomatic patients with carotid stenosis. 23 CREST is a pivotal study of para-mount importance because it evaluates carotid stenting in a subset of patients that has been shown to gain the most benefit from carotid revascularization.
Candidates for CREST will be carotid stenosis patients who have experienced a nondisabling stroke, transient ischemic attack, or amaurosis fugax within 6 months of enrollment. Originally restricted to high-grade symptomatic lesions, the CREST protocol has been revised to lower the threshold symptomatic lesion to Ն50% stenosis, in accordance with the latest findings of the North American Symptomatic Carotid Endarterectomy Trial (NASCET). 24 Hence, the duplex imaging criterion is a Ն70% internal carotid artery stenosis; in patients with intermediate stenoses (50%-70% by duplex), eligibility will be determined by angiographic documentation of a Ն50% stenosis. Clinical and anatomical exclusion criteria will conform to NASCET guidelines. The primary endpoints will be (1) 30-day death, stroke, and myocardial infarction, and (2) ipsilateral stroke during the 4-year follow-up period. Secondary analyses will compare periprocedural mortality and economic and quality of life measures between the two procedures. Moreover, CREST's commitment to evaluate differential efficacy of CEA and carotid stenting according to gender constitutes a major secondary analysis.
This study has been scrupulously designed to allow comparison of two different clinical treatment strategies. 23 CEA may be undertaken on the basis of duplex assessment alone, and carotid stenting will be performed with adjunctive contrast angiography by use of a single stenting system (ACCULINK; Guidant, Temecula, CA, USA). It is anticipated that neuroprotection will be used in stent procedures. This unique feature should favor participation by surgeons and will provide the first largescale prospective evaluation of CEA under these circumstances. Another special aspect of CREST is its commitment to the recruitment of women and minorities, groups that have never before been adequately represented in carotid surgery trials.
To ensure ''state of the art'' results, great emphasis has been placed on credentialing of both surgeons and stent operators. Notably, stent operators must have completed up to 20 carotid stent cases to be considered for CREST. In addition, the Interventional Management Committee will review the results of up to 20 independently and prospectively audited ACCULINK stent cases.
The CREST study will require 2500 randomized patients to be adequately powered to show a difference between the two therapies. This will represent the largest trial of its kind and will require a massive recruitment effort involving ഠ50 centers. If each center could average a modest recruitment of 2 to 3 patients per month, this phase could be completed in 2 years! For FDA purposes, analysis of results could begin 12 months after enrollment of the last patients. It is important to recognize that, for both techniques, the expected cluster of periprocedural endpoints will largely determine the final outcome of the study. Given this and the reasonable late outcomes seen with carotid stenting, 10,14,25 a 12-month analysis will likely provide the most valuable information. However, additional clinical followup to 4 years is a crucial component of CREST.
Priority must be given to recruitment efforts for the CREST study. However, for a variety of logistical, scientific, and ethical reasons, many patients with significant carotid stenoses will not be eligible for participation in CREST. This will represent a very large population of asymptomatic patients, the elderly (Ն80 years), and people at higher risk for CEA owing to comorbidities. For many reasons, these CREST-ineligible patients should not be lost to rigorous prospective evaluation.
CAROTID REVASCULARIZATION WITH ENDARTERECTOMY OR STENTING SYSTEMS (CARESS)
The INTERNATIONAL SOCIETY OF ENDOVASCULAR SPECIALISTS (ISES) recently submitted an Investigational Device Exemption (IDE) to the FDA for approval of the CARESS study so that symptomatic patients excluded from CREST may be studied. In addition, some asymptomatic patients will be included in the CARESS clinical cohort, but patients eligible for CREST will be excluded from CARESS. The threshold lesion for symptomatic patients will be a du-plex-defined Ն50% stenosis; asymptomatic patients will require a Ն75% stenosis to be included in CARESS. All ultrasound scans and angiograms will be subjected to central core laboratory evaluation.
Stent operators will be required to have completed a minimum of 50 successful carotid cases. In CARESS, all procedures will be performed using a designated stent and neuroprotection system under an FDA IDE. In the majority of high-volume centers, it is likely that more than one stent/protection system will be available. The CARESS investigators do not expect to detect intrasystem differences in stent outcomes during the course of the study.
CARESS is designed as an observational study to demonstrate the effectiveness of carotid stenting with cerebral protection compared to a contemporaneous group of CEAs. The primary endpoints are similar to those in CREST. Surgical outcomes will be obtained from a concurrent prospective registry of CEAs undertaken at the study sites. Appropriate proportional hazards models will take into account the expected baseline differences in risk profiles between the two cohorts.
The FDA approved the IDE for CARESS on March 14, 2001 . Once underway, CARESS will provide adjunctive information on the management of patients with carotid occlusive disease. The less rigorous, observational design of CARESS will generate outcome data on patients treated with carotid stenting and CEA who fall outside the closely defined inclusion and exclusion criteria for CREST. Data from randomized clinical trial like CREST and an observational study such as CARESS will likely provide the information the medical community requires to properly evaluate the usefulness of carotid stenting. It is ''time to get to get together to get some answers.''
